临床微生物学档案

  • 国际标准期刊号: 1989-8436
  • 期刊 h 指数: 22
  • 期刊引用分数: 7.55
  • 期刊影响因子: 6.38
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 全球影响因子 (GIF)
  • 开放档案倡议
  • 中国知网(CNKI)
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • Scimago期刊排名
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Peritoneal Dialysis Related Candida Peritonitis: A 16-year Single-Centre Experience

Upma Narain and Arvind Gupta

Background: Fungal peritonitis represents one of the most serious complications in patients on Continuous Ambulatory Peritoneal Dialysis therapy. In the present study we have analyzed peritoneal dialysis patients who have developed Candida peritonitis.

Methods & Findings: In between January 2000 to August 2015, in our retrospective study we identified 65 episodes of peritoneal dialysis associated with fungal peritonitis, and examined their demographic features, predictors, incidence of Candida species and their outcome. Among 65 fungal episodes 89.3% were Candida species, 1.5% yeast and 9.2% were dimorphic fungi. Non-albicans Candida species outnumbered the Candida albicans. Significant association was found between predictors and pathogens. Previous bacterial peritonitis episode was strongest predictor amongst the all. On analyzing the outcome data obtained from all 65 patients through Chi test, we inferred that non-albicans Candida species were the major cause of death in majority of the patients. The similar trend was found in almost all the primary causes of End Stage renal disease test set, however the sample size (in others) was less than the minimum number of cases to be inferred statistically sound. The Loss of life parameters was found to be more than 3 fold higher in cases of non-albicans Candida species.

Conclusion: This study emphasizes that non-albicans Candida species appeared to be the significant pathogen in cases of Peritoneal Dialysis associated with fungal peritonitis. Hence, the study concludes that to reduce morbidity we need to start empirical antifungal coverage by taking into account their local epidemiological prevalence and their intrinsic behavior to antifungal drugs. Therefore to reduce mortality and chances of treatment failure we have to ensure rapid fungal species identification and risk assessment.